SYSTEMICALLY AND LOCALLY ADMINISTERED CELLS FOR NEUROPATHIC PAIN

• US 20100159025A1
• Filed: 12/19/2009
• Published: 06/24/2010
• Est. Priority Date: 06/27/2003
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Kramer, Brian C., Herzberg, Uri
• Application Number:
  US12/642,775
• Publication Number:
  US 20100159025A1
• Time in Patent Office: Days
• US Class Current: 424/583
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system

Abstract

Methods for treating chronic pain, neuropathic pain or spasticity are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of nerves in the patient to decrease chronic pain, neuropathic pain or spasticity. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

Claims

1. A method of treating a subject having neuropathic pain, said method comprising administering to the subject a composition comprising a population of isolated umbilical cord tissue-derived cells such that neuropathic pain is treated.

6. The method of any of claims 1-2, wherein the population of isolated umbilical cord tissue-derived cells is administered locally to a tissue site.

7. The method of claim 6, wherein the population of isolated umbilical cord tissue-derived cells are administered proximal or distal to the tissue site by use of a catheter, syringe, shunt, stent, microcatheter, pump, implantation with a device, or implantation with a scaffold.

8. The method of any of claims 1-2, wherein the population of isolated umbilical cord tissue-derived cells is administered systemically.

9. The method of claim 8, wherein the population of isolated umbilical cord tissue-derived cells are administered intravenously, interperitoneally, intraarterial, or via syringes with needles or catheters with or without pump devices.

10. The method of claim 6, wherein the population of isolated umbilical cord tissue-derived cells comprises pharmaceutically acceptable carriers and/or diluents selected from the group consisting of:

saline, aqueous buffer solutions, solvents, dispersion media composition and a mix thereof.

11. The method of claim 6, wherein the population of isolated umbilical cord tissue-derived cells further comprises one or more hydrogels which are selected from the group consisting of:

collagen, atelocollagen, fibrin, thrombin-fibrin, and a mix thereof.

2. A method of treating a subject having neural spasticity, said method comprising administering to the subject a composition comprising a population of isolated umbilical cord tissue-derived cells such that neural spasticity is treated.

3. A method of treating a subject having neuropathic pain, said method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat neuropathic pain, wherein said cells are derived from human umbilical cord tissue substantially free of blood and are capable of self-renewal and expansion in culture.

4. The method of claim 3, wherein the umbilical cord tissue-derived cells do not express hTERT or telomerase.

5. The method of claim 3, wherein the umbilical cord tissue-derived cells are negative for CD117.

12. The method of any of claim 3, wherein the population of isolated umbilical cord tissue-derived cells comprises cells are genetically modified to produce therapeutically useful gene products or to produce agents to facilitate or support neural tissue formation or growth.

13. A composition used for treating chronic pain, said composition comprising a population of umbilical cord tissue-derived cells.

16. The composition of any of claims 13-15, said composition comprising pharmaceutically acceptable carriers and/or diluents selected from the group consisting of:

saline, aqueous buffer solutions, solvents, dispersion media composition and a mix thereof.

17. The composition of any of claims 13-15, said composition comprising further comprising one or more hydrogel selected from the group consisting of:

collagen, atelocollagen, fibrin, thrombin-fibrin, and a mix thereof.

18. The composition of any of claims 13-15, said composition further comprising a population of cells derived from one or more of the following tissues:

dermal tissue, vascular tissue, connective tissue, cartilage, adipose tissue, muscle tissue, tendons or ligaments.

19. The composition of any of claims 13-15, where said population of cells comprises genetically modified cells that produce therapeutically useful gene products, produce agents to facilitate or support neural tissue formation or growth, or produce factors to recruit progenitor cells to the area of neural damage.

14. A composition used for treating neuropathic pain, said composition comprising a population of umbilical cord tissue-derived cells.

15. A composition used for treating spasticity, said composition comprising a population of umbilical cord tissue-derived cells.

20. A kit used for treating chronic pain, neuropathic pain or spasticity, said kit comprising a population of umbilical cord tissue-derived cells, a pharmaceutically acceptable carrier and/or diluent and a hydrogel.

21. A kit used for treating chronic pain, neuropathic pain or spasticity, said kit comprising a population of hUTC cells, a pharmaceutically acceptable carrier and/or diluent and a collagen or fibrin-thrombin construct.